Halozyme Therapeutics
 | |
| Public (NASDAQ: HALO) | |
| Industry | Biopharmaceutical |
| Founded | 1998 |
| Headquarters | San Diego, California, USA |
Key people | Dr. Helen Torley, President & CEO |
| Products | Biologics |
| Revenue |
 $ 3,799,521 USD (2007) |
Number of employees | 200 |
| Website | www.halozyme.com |
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.